Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benazepril · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Benazepril HCl 40 mg Tablets | DRUG | 1 x 40 mg, single-dose fed |
| Lotensin® 40 mg Tablets | DRUG | 1 x 40 mg, single-dose fed |
Inclusion Criteria: * Screening Demographics: All volunteers for selected for this study will be healthy men or women 19 years of age or older at the time of dosing. The weight range will not exceed ±20% for height and body frame as per Desirable Weights for Men - 1983 Metropolitan height and Weigh...
Benazepril is a small molecule drug developed by Teva Pharmaceutical Industries Limited (ticker: TEVA). It is an ACE inhibitor that has been studied in Phase 1 clinical trials. The specific medical conditions it is intended to treat have not been disclosed.
Benazepril targets ACE (angiotensin-converting enzyme). It acts as an inhibitor of this enzyme. By inhibiting ACE, benazepril affects the renin-angiotensin system, which is involved in blood pressure regulation.
Benazepril is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker symbol TEVA. Teva is the company responsible for the development of this drug candidate.
Benazepril is in Phase 1 clinical development. It has completed two Phase 1 trials. As an investigational drug, it has not been approved by the FDA for any indication.
Benazepril has been studied in two completed Phase 1 trials: NCT00836576, titled 'Benazepril HCl 40 mg Tablets, Fasting', and NCT00836537, titled 'Benazepril HCl 40 mg Tablets, Fed'. Both trials enrolled 40 healthy volunteers each in the United States.